Cancer Drugmaker Destroyed Records Before FDA Inspection

$50 Million in Fines and Forfeiture

Nick Mulcahy

March 05, 2021

A company that manufacturer ingredients for cancer drugs used in the United States has pleaded guilty to concealing and destroying records prior to an inspection by the Food and Drug Administration (FDA) and will pay $50 million in fines and forfeiture.

The company, Fresenius Kabi Oncology Limited, has also agreed to implement a compliance and ethics program to adhere to US standards.

Fresenius Kabi owns and operates a plant in Kalyani, West Bengal, India, that manufactured active pharmaceutical ingredients used in "various cancer products" distributed to the US, according to a Department of Justice (DOJ) statement.

The FDA conducted a plant inspection at the factory in India in 2013. The company removed and destroyed records that "would have revealed [that it] was manufacturing ingredients in contravention of FDA requirements," the DOJ said.

Fresenius Kabi Oncology Limited was charged with violating the Federal Food, Drug, and Cosmetic Act by failing to provide required records to FDA investigators. The company is guilty of a misdemeanor. As noted above, it will pay $50 million to the US government, which comprises a $30 million fine and $20 million forfeiture.

"Fresenius Kabi Oncology Limited's conduct put vulnerable patients at risk. The Department of Justice will continue to work with FDA to prosecute drug manufacturers who obstruct these inspections," said Acting Assistant Attorney General Brian Boynton of the DOJ's Civil Division.

Company Responds

The employees who failed to provide the FDA with the required information were terminated in 2013, according to a statement sent to Medscape Medical News from the parent corporation, Fresenius Kabi in Bod Homburg, Germany.

"We continuously strive for the highest standards in pharmaceutical manufacturing," said Mats Henriksson, company CEO.

The US agency did not specify which ingredients or what cancer drugs were affected in its statement.

The company website says that its oncology products include ingredients for injectables (liquid, dry, lyophilized), tablets, and capsules.

Case documents were made public in February, but were not yet accessible when this story went to press. The documents include the criminal indictment, which contains the comprehensive details of the case.

"We are working with the court to get the documents online as the case is now unsealed," said Nicholas Dickinson, assistant US attorney in Nevada, in a February email to Medscape Medical News.

Nick Mulcahy is an award-winning senior journalist for Medscape, focusing on oncology, and can be reached at and on Twitter: @MulcahyNick.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: